Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBRX5
- Development stage
- Preclinical
- Lead developer
- Stramsen Biotech
01
Overview
SBRX5 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of HIV infection and immunodeficiency. It is part of the company's SBRX series, which includes over 30 drug candidates derived from a proprietary medicinal plant database. SBRX5 is designed to control HIV infection and enhance the patient's immune system. The development of this candidate aligns with Stramsen Biotech's focus on plant-based medicines as alternatives to synthetic drugs, aiming to provide therapeutic options with improved safety profiles and reduced side effects. While the specific botanical components and molecular targets are not publicly disclosed, the drug is positioned as a natural therapeutic for chronic viral management and immune support.
Beyond the preview
Go deeper on SBRX5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBRX5.